Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.
Merck said the FDA has agreed to conduct a priority review of Merck's application to expand the current approved usage of Gardasil -- a vaccine used to prevent infection by the human papillomavirus, or HPV -- from children and women ages 9-26 to women ages 27 through 45.
The pharmaceutical company said Gardasil is used to prevent cervical cancer, precancerous or dysplastic lesions and genital warts caused by HPV.
Gardasil, sold in some countries as Silgard, has been approved in 100 nations, including the United States, the European Union, Mexico, Australia, Taiwan, Canada, New Zealand and Brazil, Merck said.
Copyright 2008 by United Press International
Related stories:
Worldwide distribution of cervical cancer virus is consistent with vaccine targets
The variety of human papilloma viruses that cause invasive cervical cancer cases worldwide are largely consistent across continents, according to a new study from the University of North Carolina at Chapel Hill.
NIAID will not move forward with the PAVE 100 HIV Vaccine Trial
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.
Osteoporosis drug fosamax linked to heart problem
Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine.
MIT unraveling secrets of red tide
In work that could one day help prevent millions of dollars in economic losses for seaside communities, MIT chemists have demonstrated how tiny marine organisms likely produce the red tide toxin that periodically shuts down U.S. beaches and shellfish beds.
New chemistry approach promises less expensive drugs
With a newly discovered method of assembling organic molecules, a team of Princeton University chemists may have found a way to sidestep many of the expensive and hazardous barriers that stand in the way of drug development.
Some men want girls' vaccine, too
Some British gay men want to be vaccinated with the drug approved to protect girls from cervical cancer, saying it could help them, too.
Africa's first large-scale HIV vaccine study launches
The launch of the first large-scale study to evaluate a candidate HIV vaccine on the African continent was announced today by study collaborators in the United States and South Africa. The trial will involve up to 3,000 participants at five sites throughout South Africa and is expected to continue for four years.
Researchers target silicon chips for biomolecular devices
Arizona State University researchers in the Ira A. Fulton School of Engineering are key contributors to an $11.7 million, multicollaborative Defense Advanced Research Project Agency research project developing novel hybrid biomolecular nanodevices and systems for potential application as biosensors in areas such as disease detection, pharmaceutical drug-testing, drug-delivery systems and health monitoring.